Novel technology developed by HeartFlow Inc. significantly reduces the need for invasive procedures to diagnose patients suspected of having coronary artery disease.
The ITN team has just returned from the Healthcare Information and Management Systems Society’s (HIMSS16) annual conference in Las Vegas, where more than 40,000 healthcare IT professionals gathered to learn about and share information on optimizing healthcare outcomes using information technology.
If you enjoy this content, please share it with a colleague
Pyrexar Medical announced a new distribution partnership with Clinitech Co. Ltd., bringing Pyrexar’s hyperthermia technologies into Cuba, the West Indies, Panama and Venezuela.
April 1, 2016 — Augmenix Inc. announced the publication of the SpaceOAR System U.S. Clinical Trial results of the application technique and impact on prostate intensity modulated radiation therapy (IMRT).
Designed to act as a temporary spacer, the absorbable hydrogel pushes the rectum away from the prostate and reduces rectal radiation injury in men undergoing prostate cancer radiotherapy.
April 1, 2016 — Pyrexar Medical announced the achievement of ISO 13485 Certification and CE re-certification for its line of hyperthermia products for cancer treatment.
ISO 13485 represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices. The ISO standard is also a required compliance to do business in the European Union.
The CE Mark allows Pyrexar to ship medical devices to any of the 27 member states of the EU.
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy development paradigm, as well as his strategic vision to optimize the implementation of next-generation immunotherapies.
March 31, 2016 — Medical diagnostic imaging provider Digirad Corp. posted an article to their website discussing updates to appropriate use criteria (AUC) for clinical decision support (CDS) coming in 2016.
New technology has enabled doctors to administer higher doses of radiation to prostate cancer patients with fewer side effects. However, a new study shows that escalating the dose may not actually help a patient in the long term, at least not patients with localized prostate cancer.
